Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

50.14 +0.38 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine
The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in... 
Via TokenRing AI
Topics Artificial Intelligence Economy
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why Immuneering Stock Soared Over 40% After-Hours Today
Via Stocktwits
Is Sanofi Gaining or Losing Market Support?
 
Via Benzinga
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More
Via Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
Via Stocktwits
Novavax Amends Deal With Sanofi, Broadens Partnership
The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate. 
Via Stocktwits
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
Amgen Expands US Manufacturing Network Amid New Tariff Policy
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ:... 
Via Benzinga
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025. 
Via Benzinga
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability
Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions. 
Via Benzinga
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Why Nektar Therapeutics Rippled Higher This Week
The company's competitive positioning might be stronger now, after disappointing results from a key rival. 
Via The Motley Fool
Topics Intellectual Property
What's Going On With Nektar Therapeutics Stock On Thursday?
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
Why Is Sanofi Stock Falling Thursday?
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
This Monster Beverage Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.